Linked Life Data

12756634

Source:http://linkedlifedata.com/resource/pubmed/id/12756634

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-5-20
pubmed:abstractText
An established model of arterial injury was used to evaluate the ability of the glycoprotein (GP) IIb/IIIa antagonist abciximab to inhibit platelet function and deter thrombus formation in cats. The study was a blinded evaluation, with control cats receiving aspirin and placebo and treatment cats receiving aspirin plus abciximab. The group treated with aspirin plus abciximab had significantly (P<.05) less thrombus formation based on a smaller number and frequency of cyclic flow reductions and reduced luminal thrombus area than cats treated with aspirin plus placebo. Abciximab administered in addition to aspirin also resulted in significant (P<.05) inhibition of platelet function based on mucosal bleeding time and change in bleeding time from baseline.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1528-3593
pubmed:author
pubmed:issnType
Print
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
35-46
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Effects of the glycoprotein IIb/IIIa antagonist abciximab on thrombus formation and platelet function in cats with arterial injury.
pubmed:affiliation
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't